Physician

Robert Glenn Carter, M.D.

According to 2025 Medicare claims, Robert Carter, M.D. (NPI: 1922192418) practices internal medicine in the Hinesville, GA market, with the plurality of this provider's patient population coming from Liberty, GA. This provider's primary affiliated billing organization is PRIVIA MEDICAL GROUP OF GEORGIA LLC (NPI: 1013313857; TIN: 202265068) and primary practice location at 31313-3657. Carter is affiliated with the Privia Quality Network of Georgia (ACO ID: A3236), participating under the MSSP model.

Carter's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 94 traditional Medicare patients, billed 369 HCPCS/CPT codes, and received $15,394 in Medicare payments. The top billing code was G0439 (Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit). Part D data shows 2,551 prescription claims across 288 beneficiaries totaling $250,038 in drug costs, led by Farxiga (Dapagliflozin Propanediol). 2020 DME data shows 39 claims. Open Payments data shows 211 records totaling $266,835. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has fallen sharply in recent years, from $56,337 to $15,394. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $194,867 and ending at $250,038. In contrast, DME billing represents a smaller volume and declined steadily, from $7,335 to $980.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	211	1,916	$56,337
2016	211	1,872	$55,304
2017	215	1,675	$50,930
2018	215	1,691	$46,752
2019	199	1,204	$45,038
2020	184	914	$32,240
2021	337	1,208	$47,111
2022	170	886	$37,806
2023	140	562	$23,506
2024	94	369	$15,394

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	189	4,237	$194,867
2016	210	3,710	$222,111
2017	216	3,861	$264,310
2018	206	3,624	$277,178
2019	215	2,320	$220,027
2020	220	1,981	$166,400
2021	238	2,165	$190,226
2022	256	2,014	$401,146
2023	294	2,304	$361,492
2024	288	2,551	$250,038

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	28	144	$6,385
2016	13	70	$1,453
2017	N/R	62	$1,519
2018	N/R	50	$1,783
2019	N/R	52	$2,173
2020	N/R	39	$1,014
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
G0439	Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit	45	45	$113
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	85	165	$43
90661	Influenza vaccine, trivalent derived from cell cultures	18	18	$36
36415	Insertion of needle into vein for collection of blood sample	30	33	$8
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	35	47	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Farxiga	Dapagliflozin Propanediol	22	1,750	$33,844
Eliquis	Apixaban	26	1,265	$25,227
Ozempic	Semaglutide	12	504	$15,223
Januvia	Sitagliptin Phosphate	11	630	$12,251
Shingrix	Varicella-Zoster Ge/As01b/Pf	49	339	$10,986

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	16	$483	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	195	$266,352	Invivyd Inc
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Robert Glenn Carter, M.D.?

Tedicare shows public-source Medicare data for Robert Glenn Carter, M.D. (NPI 1922192418), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Robert Glenn Carter, M.D. have ACO affiliation data?

Robert Glenn Carter, M.D. is shown with ACO affiliation data for Privia Quality Network of Georgia (MSSP, ACO ID A3236).

What billing organization is linked to Robert Glenn Carter, M.D.?

Robert Glenn Carter, M.D. is linked to PRIVIA MEDICAL GROUP OF GEORGIA LLC (billing NPI 1013313857) in the available physician profile data.

Does Robert Glenn Carter, M.D. have Open Payments data?

Robert Glenn Carter, M.D. has 211 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.